502 related articles for article (PubMed ID: 27432743)
1. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
[TBL] [Abstract][Full Text] [Related]
4. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.
Kukreja A; Lasaro M; Cobaugh C; Forbes C; Tang JP; Gao X; Martin-Higueras C; Pey AL; Salido E; Sobolov S; Subramanian RR
Nucleic Acid Ther; 2019 Apr; 29(2):104-113. PubMed ID: 30676254
[TBL] [Abstract][Full Text] [Related]
5. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
[TBL] [Abstract][Full Text] [Related]
6. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
7. Re: An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Assimos DG
J Urol; 2017 May; 197(5):1297-1298. PubMed ID: 29539912
[No Abstract] [Full Text] [Related]
8. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
9. New therapeutics for primary hyperoxaluria type 1.
Dejban P; Lieske JC
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883
[TBL] [Abstract][Full Text] [Related]
10. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
Forbes TA; Brown BD; Lai C
Br J Clin Pharmacol; 2022 Jun; 88(6):2525-2538. PubMed ID: 34022071
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
Zabaleta N; Barberia M; Martin-Higueras C; Zapata-Linares N; Betancor I; Rodriguez S; Martinez-Turrillas R; Torella L; Vales A; Olagüe C; Vilas-Zornoza A; Castro-Labrador L; Lara-Astiaso D; Prosper F; Salido E; Gonzalez-Aseguinolaza G; Rodriguez-Madoz JR
Nat Commun; 2018 Dec; 9(1):5454. PubMed ID: 30575740
[TBL] [Abstract][Full Text] [Related]
13. Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.
Fargue S; Knight J; Holmes RP; Rumsby G; Danpure CJ
Biochim Biophys Acta; 2016 Jun; 1862(6):1055-62. PubMed ID: 26854734
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyproline metabolism in mouse models of primary hyperoxaluria.
Knight J; Holmes RP; Cramer SD; Takayama T; Salido E
Am J Physiol Renal Physiol; 2012 Mar; 302(6):F688-93. PubMed ID: 22189945
[TBL] [Abstract][Full Text] [Related]
15. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
Martin-Higueras C; Luis-Lima S; Salido E
Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264
[TBL] [Abstract][Full Text] [Related]
16. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene.
Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567
[TBL] [Abstract][Full Text] [Related]
17. Hepatic alanine-glyoxylate aminotransferase activity and oxalate metabolism in vitamin B6 deficient rats.
Nishijima S; Sugaya K; Morozumi M; Hatano T; Ogawa Y
J Urol; 2003 Feb; 169(2):683-6. PubMed ID: 12544342
[TBL] [Abstract][Full Text] [Related]
18. Primary hyperoxaluria type 1: novel therapies at a glance.
Bacchetta J; Lieske JC
Clin Kidney J; 2022 May; 15(Suppl 1):i17-i22. PubMed ID: 35592618
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
